**Memorandum**

Date: February 25, 2019

To: Pymaceuticals Head of Drug Development

From: Victor Chen, Chief Data Analyst

Re: Squamous Cell Carcinoma Mouse Study

To whom it may concern,

Regarding the results of the 45-day squamous cell carcinoma study, please find the conclusions below:

1. Only mice treated with Capomulin and Ramicane saw a reduction in mean tumor volume from start of treatment. Mice treated with Ceftamin, Infubinol, Propriva, and Zoniferol observed an increase in mean tumor volume, but were more efficacious than placebo in limiting tumor volume.
2. All treatments, except for ketapril, outperformed placebo in limiting the number of metastatic sites. However, the mean number of metastatic sites were not statistically significantly different between placebo and ketapril.
3. Lastly, Capomulin and Ramicane treated mice saw much higher survival rates as compared to all other treatments. Infubinol, Ketapril, and Propriva saw survival rates less than or equal to that of placebo and are therefore not recommended for further study.

Regards,

Victor Chen